Earlier, clinical trial of anti-IL-5, and recent clinical trial with anti-IL-13 reported reduced esophageal eosinophilia, but both failed to achieve primary endpoint goals for EoE therapy [123]. The gene discussed is IL5; the disease is eosinophilic esophagitis.